TMCnet News

Scorpius Holdings Achieves Major Milestone with cGMP Facility Validation for Microbial Manufacturing
[May 15, 2024]

Scorpius Holdings Achieves Major Milestone with cGMP Facility Validation for Microbial Manufacturing


DURHAM, N.C., May 15, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the successful validation of its microbial facilities, marking a significant milestone in the Company's operations. This validation signifies that Scorpius’ microbial cleanrooms are now officially approved to manufacture current Good Manufacturing Practice (cGMP) microbial biologic drugs, underscoring the Company's commitment to quality and regulatory compliance.

Scorpius facilities have already garnered considerable interest, with a backlog of bookings from client programs. This achievement not only demonstrates Scorpius' capability to meet the regulatory and client driven high standards required for contract manufacturing of microbial biologics but also highlights the trust and confidence its clients place in its services.

In conjunction with the facility qualifications, Scorpius is also streamlining its operations by transitioning environmental monitoring responsibilities to internal teams, while it migrates from the previous reliance on third-party services. This shift is expected to allow for greater efficiency, further enhancing the Company's robust ability to deliver high-quality biomanufacturing services.

“Scorpius has experienced strong interest in our microbial capabilities, and we continue to add additional opportunities to our pipeline for 2024 and 2025,” stated Jeff Wolf, CEO of Scorpius Holdings. “This validation confirms our commitment to high-quality, state-of-the-art microbial production. We are dedicated to leveraging our advanced capabilities to support our clients' needs and contributing to the advancement of breakthrough therapies.”

“Tis validation is a testament to Scorpius’ rigorous quality standards and our dedication to supporting the development and manufacturing of microbial products. With this achievement, Scorpius is poised to further solidify its position as a leader in clinical scale microbial manufacturing, offering our clients unparalleled quality and service,” concluded Wolf.



Scorpius Holdings, Inc.

Scorpius Holdings Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.


Forward-Looking Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as the transition of environmental monitoring responsibilities from third-parties to internal teams  being expected to allow for greater efficiency, further enhancing the Company's robust ability to deliver high-quality biomanufacturing services; continuing to add additional opportunities to the Company’s pipeline for 2024 and 2025; Scorpius being poised to further solidify its position as a leader in clinical scale microbial manufacturing, offering our clients unparalleled quality and service.  Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to continue to validate its microbial facilities; expand its large molecule biomanufacturing CDMO services and continue to grow revenue; the Company’s financing needs, its cash balance  being sufficient to sustain operations  and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to  obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as  a pure- play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.

Media and Investor Relations Contact
David Waldman
+1 919 289 4017
[email protected]

 


Primary Logo


[ Back To TMCnet.com's Homepage ]